Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2, Single-Arm Trial of Zanzalintinib (XL092) With MO-03 (CBM588 Capsule) in Patients With Metastatic Renal Cell Carcinoma (mRCC) After Progression to Immunotherapy

NCT07578025 is registered in ClinicalTrials.gov with City of Hope Medical Center as lead sponsor.

NCT NCT07578025
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07578025 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2, Single-Arm Trial of Zanzalintinib (XL092) With MO-03 (CBM588 Capsule) in Patients With Metastatic Renal Cell Carcinoma (mRCC) After Progression to Immunotherapy
Lead sponsor
City of Hope Medical Center
Phase
Phase 2
Overall status
Not yet recruiting
Start date
November 28, 2026
Completion date
June 24, 2028
Enrollment
34 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic clear cell renal cell carcinoma, stage iv renal cell cancer ajcc v8